JP2007504259A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504259A5 JP2007504259A5 JP2006525704A JP2006525704A JP2007504259A5 JP 2007504259 A5 JP2007504259 A5 JP 2007504259A5 JP 2006525704 A JP2006525704 A JP 2006525704A JP 2006525704 A JP2006525704 A JP 2006525704A JP 2007504259 A5 JP2007504259 A5 JP 2007504259A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- agent according
- made agent
- pharmaceuticals
- pharmaceuticals made
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- HESCAJZNRMSMJG-HGYUPSKWSA-N epothilone A Natural products O=C1[C@H](C)[C@H](O)[C@H](C)CCC[C@H]2O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C HESCAJZNRMSMJG-HGYUPSKWSA-N 0.000 claims description 17
- QXRSDHAAWVKZLJ-OXZHEXMSSA-N Epothilone B Natural products O=C1[C@H](C)[C@H](O)[C@@H](C)CCC[C@@]2(C)O[C@H]2C[C@@H](/C(=C\c2nc(C)sc2)/C)OC(=O)C[C@H](O)C1(C)C QXRSDHAAWVKZLJ-OXZHEXMSSA-N 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- QXRSDHAAWVKZLJ-PVYNADRNSA-N epothilone B Chemical group C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 QXRSDHAAWVKZLJ-PVYNADRNSA-N 0.000 claims description 15
- 230000002062 proliferating effect Effects 0.000 claims description 12
- FODFUEDBIXOGNY-UHFFFAOYSA-N 7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[1-(2-methylsulfanyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione Chemical compound S1C(SC)=NC(C=C(C)C2OC(=O)CC(O)C(C)(C)C(=O)C(C)C(O)C(C)CCCC3(C)OC3C2)=C1 FODFUEDBIXOGNY-UHFFFAOYSA-N 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 8
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 229960002949 fluorouracil Drugs 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- -1 2-methylsulfanyl-thiazol-4-yl Chemical group 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 238000011255 standard chemotherapy Methods 0.000 claims description 3
- 229920002554 vinyl polymer Polymers 0.000 claims description 3
- 210000002307 prostate Anatomy 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 40
- 208000014829 head and neck neoplasm Diseases 0.000 claims 8
- 238000011068 loading method Methods 0.000 claims 7
- 238000012423 maintenance Methods 0.000 claims 7
- 208000026310 Breast neoplasm Diseases 0.000 claims 5
- 230000000973 chemotherapeutic effect Effects 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 229930013356 epothilone Natural products 0.000 claims 4
- 150000003883 epothilone derivatives Chemical class 0.000 claims 4
- 208000020816 lung neoplasm Diseases 0.000 claims 4
- 208000037841 lung tumor Diseases 0.000 claims 4
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000036457 multidrug resistance Effects 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical compound C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 2
- JZYJVWJYKHIBRA-UHFFFAOYSA-N CC1C(OC(=O)CC(C(C(=O)C(C(CCCCC2(C1O2)C)O)C)(C)C)O)C(=CC3=CSC(=N3)SC)C Chemical class CC1C(OC(=O)CC(C(C(=O)C(C(CCCCC2(C1O2)C)O)C)(C)C)O)C(=CC3=CSC(=N3)SC)C JZYJVWJYKHIBRA-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229940119336 Microtubule stabilizer Drugs 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- LZWPOLSJFGLQCE-UHFFFAOYSA-N heptadecane-5,9-dione Chemical compound CCCCCCCCC(=O)CCCC(=O)CCCC LZWPOLSJFGLQCE-UHFFFAOYSA-N 0.000 description 1
- 208000018821 hormone-resistant prostate carcinoma Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49954803P | 2003-09-02 | 2003-09-02 | |
| PCT/EP2004/009737 WO2005020989A1 (en) | 2003-09-02 | 2004-09-01 | Cancer treatment with epothilones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007504259A JP2007504259A (ja) | 2007-03-01 |
| JP2007504259A5 true JP2007504259A5 (https=) | 2007-10-25 |
Family
ID=34272839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525704A Pending JP2007504259A (ja) | 2003-09-02 | 2004-09-01 | エポチロンでの癌処置 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20060235059A1 (https=) |
| EP (1) | EP1663214A1 (https=) |
| JP (1) | JP2007504259A (https=) |
| CN (1) | CN1870995A (https=) |
| AU (1) | AU2004268377B2 (https=) |
| BR (1) | BRPI0414043A (https=) |
| CA (1) | CA2537057A1 (https=) |
| MX (1) | MXPA06002393A (https=) |
| WO (1) | WO2005020989A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1640004A1 (en) * | 2004-09-24 | 2006-03-29 | Schering Aktiengesellschaft | Use of epothilones in the treatment of bone metastases and bone tumors or cancers |
| CN100384419C (zh) * | 2005-12-02 | 2008-04-30 | 菏泽睿鹰制药集团有限公司 | 一种埃坡霉素缓释植入组合物及应用 |
| EA020954B1 (ru) | 2008-06-16 | 2015-03-31 | Бинд Терапьютикс, Инк. | Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака |
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| US8318211B2 (en) | 2008-06-16 | 2012-11-27 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| US8563041B2 (en) | 2008-12-12 | 2013-10-22 | Bind Therapeutics, Inc. | Therapeutic particles suitable for parenteral administration and methods of making and using same |
| JP2012512175A (ja) | 2008-12-15 | 2012-05-31 | バインド バイオサイエンシズ インコーポレイテッド | 治療薬を徐放するための長時間循環性ナノ粒子 |
| DK2509634T3 (en) | 2009-12-11 | 2019-04-23 | Pfizer | Stable formulations for lyophilization of therapeutic particles |
| EP2515942B1 (en) | 2009-12-15 | 2020-02-12 | Pfizer Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
| WO2011084521A2 (en) * | 2009-12-15 | 2011-07-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same |
| WO2014043618A1 (en) | 2012-09-17 | 2014-03-20 | Bind Therapeutics, Inc. | Process for preparing therapeutic nanoparticles |
| PE20170312A1 (es) | 2014-03-14 | 2017-03-30 | Pfizer | Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4820269A (en) * | 1983-03-07 | 1989-04-11 | Vanderbilt University | Mixer apparatus for controlling intravenous drug infusion |
| US5968972A (en) * | 1995-10-26 | 1999-10-19 | Baker Norton Pharmaceuticals, Inc. | Method for increasing the oral bioactivity of pharmaceutical agents |
| US6302838B1 (en) * | 1998-02-25 | 2001-10-16 | Novartis Ag | Cancer treatment with epothilones |
| FR2775187B1 (fr) * | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
| ES2304240T3 (es) * | 2001-01-25 | 2008-10-01 | Bristol-Myers Squibb Company | Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer. |
| IL157443A0 (en) * | 2001-03-14 | 2004-03-28 | Bristol Myers Squibb Co | Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent |
| TWI287986B (en) * | 2001-12-13 | 2007-10-11 | Novartis Ag | Use of Epothilones for the treatment of the carcinoid syndrome |
| MXPA04006822A (es) * | 2002-01-14 | 2004-12-08 | Novartis Ag | Combinaciones que comprenden epotilonas y anti-metabolitos. |
| EP1503756B1 (en) * | 2002-05-01 | 2009-08-12 | Novartis AG | Epothilone derivative for the treatment of hepatoma and other cancer diseases |
| CN101389334A (zh) * | 2002-05-20 | 2009-03-18 | 高山生物科学股份有限公司 | 埃坡霉素d的给药方法 |
| BR0313198A (pt) * | 2002-08-02 | 2005-07-12 | Novartis Ag | Derivados de epotilona |
| BR0317150A (pt) * | 2002-12-09 | 2005-11-01 | Novartis Ag | Estabilizadores de microtúbulos em stents para o tratamento de estenose |
| BRPI0412000A (pt) * | 2003-06-27 | 2006-08-15 | Novartis Ag | tratamento de cáncer com epotilonas |
-
2004
- 2004-09-01 AU AU2004268377A patent/AU2004268377B2/en not_active Ceased
- 2004-09-01 CN CNA2004800313316A patent/CN1870995A/zh active Pending
- 2004-09-01 JP JP2006525704A patent/JP2007504259A/ja active Pending
- 2004-09-01 MX MXPA06002393A patent/MXPA06002393A/es not_active Application Discontinuation
- 2004-09-01 WO PCT/EP2004/009737 patent/WO2005020989A1/en not_active Ceased
- 2004-09-01 EP EP04764699A patent/EP1663214A1/en not_active Ceased
- 2004-09-01 CA CA002537057A patent/CA2537057A1/en not_active Abandoned
- 2004-09-01 BR BRPI0414043-5A patent/BRPI0414043A/pt not_active IP Right Cessation
- 2004-09-01 US US10/570,850 patent/US20060235059A1/en not_active Abandoned
-
2008
- 2008-11-12 US US12/269,293 patent/US20090069394A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wu et al. | Nanomedicine applications in the treatment of breast cancer: current state of the art | |
| Ko et al. | A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer | |
| Patel et al. | Exploring the potential of P-glycoprotein inhibitors in the targeted delivery of anti-cancer drugs: a comprehensive review | |
| Lu et al. | Hyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapy | |
| Rivera et al. | Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors | |
| JP2008530248A5 (https=) | ||
| JP2006503919A5 (https=) | ||
| Lee et al. | Development of novel chemotherapeutic agents to evade the mechanisms of multidrug resistance (MDR) | |
| JP2007504259A5 (https=) | ||
| Yogesh et al. | Biosynthesized platinum nanoparticles inhibit the proliferation of human lung-cancer cells in vitro and delay the growth of a human lung-tumor xenograft in vivo:-In vitro and in vivo anticancer activity of bio-Pt NPs | |
| JP2003533485A5 (https=) | ||
| CN110478487B (zh) | 一种大环内酯化合物在逆转肿瘤多药耐药增强抗肿瘤疗效方面的应用 | |
| JP2021500349A5 (https=) | ||
| Muggia et al. | Novel taxanes | |
| JP2022527334A5 (https=) | ||
| Denduluri et al. | Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer | |
| Cortés-Funes | New treatment approaches for lung cancer and impact on survival | |
| Bystricky et al. | Patupilone in cancer treatment | |
| Casaluce et al. | Emerging mitotic inhibitors for non-small cell carcinoma | |
| JP2024511354A5 (https=) | ||
| Kim et al. | Efficacy of nano‐particulated, water‐soluble erlotinib against intracranial metastases of EGFR‐mutant lung cancer | |
| Zhang et al. | Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors | |
| CN107041886A (zh) | 脱环氧埃坡霉素衍生物制剂、制备及其治疗肿瘤的应用 | |
| JP2005511663A5 (https=) | ||
| JP2005511663A (ja) | 癌に対する医薬の製造のための、他の抗腫瘍性剤と組み合わせたファルネシルタンパク質トランスフェラーゼインヒビターの使用 |